LEIDEN, The Netherlands and SEATTLE, Washington, March 11, 2010 /PRNewswire/ -- ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the conclusion of the first Phase II trial testing its unique new hemostat Fibrocaps(TM). Promising preliminary data from the European multicenter, open-label trial show compelling safety and efficacy (time to hemostasis) profiles for Fibrocaps, and good performance of the delivery device.
Robert J. Porte, MD, PhD, principal investigator of the Phase II trial, said: "Fibrocaps is a highly promising new hemostat that has unique characteristics and demonstrates optimal efficacy. We are fully committed to assist ProFibrix with the further development of this product and look forward to bringing this important innovation in hemostasis to the clinic."
ProFibrix recently also appointed Paul A. Frohna, MD, PhD, as Chief
Medical Officer. Dr. Frohna has extensive preclinical, clinical and
regulatory experience, as well as with designing and running clinical trials
in the U.S., Canada and Europe. He has held senior management positions at
companies such as Fibrogen Inc., CV Therapeutics, and Genentech. Dr. Frohna's
educational background includes an undergraduate pharmacy degree with Honors
from the '/>"/>
|SOURCE ProFibrix B.V.|
Copyright©2010 PR Newswire.
All rights reserved